# Who could benefit from SPINRAZA?
Keywords: SPINRAZA, SMA, 5q SMA, motor function, HFMSE, RULM, 6MWT, safety profile, real-world evidence, clinical trials

> This page provides information about the potential benefits of SPINRAZA for patients with different types of Spinal Muscular Atrophy (SMA), highlighting its efficacy, safety profile, and real-world impact on motor function and quality of life.

## Details
- [Introducing Toby](#toby): Toby, a 16-year-old with Type IIb SMA, has experienced improved mobility and independence through SPINRAZA treatment.
- [Introducing Amy](#amy): Amy, a 30-year-old with Type IIIa SMA, has preserved and improved her motor function, enabling her to enjoy art and travel with less fatigue.
- [Introducing Kam](#kam): Kam, a 37-year-old with Type IIIb SMA, aims to maintain his mobility and prevent functional decline with SPINRAZA.
- [Potential Benefits](#): SPINRAZA has demonstrated the ability to improve motor function, upper limb mobility, and walking endurance, as well as maintain independence for SMA patients.
- [Efficacy and Safety](#): With over 14,000 patients treated globally, SPINRAZA has a well-established safety and efficacy profile supported by clinical trials and real-world evidence.
- [Reporting Adverse Events](#): Guidance on reporting adverse events in the UK and Ireland is provided, along with contact details for Biogen.